|
||
|
|
|
||
|
|
For major bleeds, the Figure shows continued similarity.[118] Here major bleed seems to be significantly less with apixaban and the lower dose of dabigatran, but again in this nonstatistical alignment it is not clear how much of this apparent difference represents a real difference among the drugs versus being merely an apparent difference because of differences in populations or in the definitions of “major bleeding.”
Reiffel JA. Am J Med 2013; 126: 00-00.
[118] Tendera M, Syzdół M, Parma Z. ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation? Cardiol J. 2012;19:4-10.